The 5th Digital Pharma Europe conference

25 - 27 February 2013, Bristol-Myers Squibb HQ, Paris, France.
Digital Pharma Europe is one of the key component conferences of the ground breaking Digital Pharma Series. ExL Pharma has leveraged the global network of industry experts to further analyze global industry perceptions and pain points and match these with interactive and practical solutions. Through our conversations with ePatients, doctors and healthcare organizations, pharma marketers, brand/product managers, agencies and technology providers, the message is clear: The most sought after tool in better equipping marketing teams and progressing digital marketing strategy is the opportunity for peer-to-peer contact to enable groundbreaking technical and strategy roll out.

The 5th Digital Pharma Europe conference not only leverages the largest platform of pharmaceutical marketing expertise from our global directory of contacts to provide these deliverables, but the agenda is specifically structured to meet the varying needs and requirements for practitioners working across the breadth of brand marketing and technical support functions in European organizations.

The challenges and innovations within the digital, social media and mobile marketing space continue to develop at pace and attendees at Digital Pharma Europe can expect to benchmark, learn from and interact with senior level professionals covering the multitude of topics concerning pharma marketing business today. The below topics will be covered in a practical perspective allowing for takeaway and delivery back in the office:

  • ePatient and Doctor/Physician network's evolution and the innovative tools for their interaction with pharma: Profiling interaction of newer social media channels such as Tweet chats and video calls on Google+, and the strategies used to deliver messages to doctors
  • Examining technologies developed to communicate B2B with stakeholders
  • Discussing how to effectively monitor and manage off-label discussions, and how you can deal with open platforms for patients from a technical and regulatory oversight standpoint
  • Social listening - listening to professional and patient conversations: Organizational strategy for leveraging feedback received from consumers and physicians from multiple channels
  • Gamification and how to actually impact upon patient behavior and compliance
  • The advent on non-pharma based organizations providing preventative mobile health solutions and the impact on pharma business
  • Physician App development without pharma marketing input: The why's and how's?
  • Big Data: transitioning with handling small to big data, carefully handling patient privacy without incurring regulatory pressure
  • Building highly effective and revenue generating digital marketing teams from the ground up: examination of digital and social media marketing training and how to build digital marketing specialists from a traditional marketing background
  • Change management and transitioning your strategy to incorporate social media and digital mediums to effect behavioral responses
  • App as medical devices: understanding at what point an App transitions from being an information sharing resource to a data usable medical device. Aligning the regulatory requirements with business development and effectiveness for your sales operations
  • Multi-Channel Marketing: analyzing whether pharma marketing will become MCM at a base level in future
  • Examining how to effectively measure the ROI of MCM and covey this to senior management: what to look for, metrics, suites of tools and identification of the alterations/channels that result in a change of behavior
  • How to operate with a multimedia mix - how can pharma work with the full range, not just social media etc

Digital Pharma Europe is the only industry event that continues to be hosted by a leading pharmaceutical company. This year it will be at Bristol Myers-Squibb HQ in Paris, France.

For further information and registration, please visit:
http://www.digitalpharmaseries.com/europe/

Most Popular Now

BioNTech's statement on patent infringement lawsui…

BioNTech SE (Nasdaq: BNTX, "BioNTech") published an official statment: "BioNTech is aware of reports that Moderna has sued Pfizer and BioNTech, alleging that COMIRNATY® i...

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...